Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The importance of individually customized treatment for CLL patients

Davide Rossi • 9 Jun 2016
EHA 2016
Chronic Lymphocytic Leukemia

Davide Rossi, MD, PhD from University of Eastern Piedmont, Vercelli, Italy outlines the novel treatment options for chronic lymphocytic leukemia (CLL) patients. Due to the vast number of these new treatments doctors need to have tools to help them tailor treatments to the patient. Consequently there is a growing need to develop prognostic and predictive factors that may help in the customization of treatment. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Davide Rossi

9:02
Precision medicine in lymphoma
Anas Younes et al. • 21 Sep 2018
1:31
A short discussion of the unmet needs of CLL patients
Davide Rossi • 9 Jun 2016

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals